Chester A. Metcalf

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 362 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior

Valerie G. Brunton, Egle Avizienyte, Valerie J. Fincham et al. · Cancer Research · 2005 · 209 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O’Hare, Roy M. Pollock, Eric P. Stoffregen et al. · Blood · 2004 · 199 citations · Full text

Medicine, Medicinal Chemistry, Oncology +8

Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with <i>in vivo</i> antiresorptive activity

William C. Shakespeare, Michael G. Yang, Regine S. Bohacek et al. · Proceedings of the National Academy of Sciences · 2000 · 133 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17